18
Selecting a Treatment Regimen
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Efavirenz
(EFV)
Sustiva
®
600 mg PO once
daily, at or before
bedtime
No dosage
adjustment
necessary
Child-Pugh Class A:
• No dosage adjustment
Child-Pugh Class B/C:
• NOT recommended
Etravirine
(ETR)
Intelence
®
200 mg PO bid No dosage
adjustment
necessary
Child-Pugh Class A/B:
• No dosage adjustment
Child-Pugh Class C:
• No dosage rec.
Nevirapine
(NVP)
Viramune
®
Viramune
®
XR
• 200 mg PO bid, or
• 400 mg PO
once daily (using
Viramune XR
formulation)
Patients on HD:
• Limited data;
no dosage
recommendation
Child-Pugh Class A:
• No dosage adjustment
Child-Pugh Class B/C:
• Contraindicated
Rilpivirine
(RPV)
Edurant
®
25 mg PO once
daily
No dosage
adjustment
necessary
Child-Pugh Class A/B:
• No dosage adjustment
Child-Pugh Class C:
• No dosage rec.
Protease Inhibitors (PIs)
Atazanavir
(ATV)
Reyataz
®
400 mg PO once
daily
OR
ATV 300 mg +
RTV 100 mg PO
once daily
No dosage
adjustment for
patients with renal
dysfunction who
do not require HD
ARV-Naive
Patients on HD:
• ATV 300 mg +
RTV 100 mg
once daily
ARV-Experienced
Patients on HD:
• ATV or
ATV/r NOT
recommended
Child-Pugh Class B:
• 300 mg once daily
Child-Pugh Class C:
• NOT recommended
RTV boosting is NOT
recommended in
patients with hepatic
impairment (Child-Pugh
Class B or C).
Atazanavir/
COBI
(ATV/c)
Evotaz
®
1 tablet PO once
daily
If Used with TDF:
• NOT
recommended for
use in patients with
CrCl <70 mL/min
NOT recommended in
patients with hepatic
impairment
Table 6. Dosing of Antiretroviral Agents (cont'd)
ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily
Dose
a
Dosing in Renal
Insufficiency
b
Dosing in Hepatic
Impairment